Yan Weng

A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects

Saswata Talukdar, Yingjiang Zhou, Dongmei Li et al. · Cell Metabolism · 2016 · 488 citations · Full text

Life Sciences, Biochemistry, Endocrinology +15

Liver-specific Deletion of the NADPH-Cytochrome P450 Reductase Gene

Jun Gu, Yan Weng, Qing-Yu Zhang et al. · Journal of Biological Chemistry · 2003 · 223 citations · Full text

Life Sciences, Molecular Biology, Molecular Genetics +14

Neuroprotective effect of Apelin 13 on ischemic stroke by activating AMPK/GSK-3β/Nrf2 signaling

Jialin Duan, Jia Cui, Zhifu Yang et al. · Journal of Neuroinflammation · 2019 · 212 citations · Full text

Life Sciences, Neurobiology, Neuroscience +16

Once‐weekly administration of a long‐acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non‐human primates

Albert M. Kim, Veena Somayaji, Jennifer Dong et al. · Diabetes Obesity and Metabolism · 2017 · 139 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Protective effect of butin against ischemia/reperfusion-induced myocardial injury in diabetic mice: involvement of the AMPK/GSK-3β/Nrf2 signaling pathway

Jialin Duan, Yue Guan, Fei Mu et al. · Scientific Reports · 2017 · 127 citations · Full text

Life Sciences, Cardiology, Pharmacology +17